Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5639_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

15.09.2026

Размер:

15 Мб

Скачать

☆

<<< < Предыдущая 14 15 16 17 18 19 20 21 22 23 24 2526 / 4826 27 28 29 30 31 32 33 34 35 36 37 38 > Следующая >>>

11 Role ofGenomics andProteomics inDrug Discovery

https://t.me/med1917

biological pathways or mechanisms can be made via synthetic biology. The building of novel biological systems and functionalities made possible by synthetic biology has the potential to broaden the focus and use of omics research.

Scientic research is being accelerated, and health care is being revolutionized by emerging technologies in genomics and proteomics. These developments could lead to a better understanding of diseases, more effective medication development, and the emergence of customized medicine, in which a patient’s therapy is based on their unique proteome and genetic prole. These technologies will surely change the course of clinical treatment and biomedical research as they develop further (Duarte etal. 2019).

239

11.8.3 Future Trends inDrug Discovery

Drug research is a dynamic subject that is always changing due to scientic discoveries, technological advancements, and the growing need for novel and efcient treatments. These are a few of the major developments in drug discovery that are worth watching.

Articial intelligence and machine learning are two elds that are revolutionizing drug development through their ability to analyse large amounts of data, predict drug-target interactions, nd possible therapeutic candidates, and optimize clinical trial designs. AI-driven medication discovery lowers costs and speeds up the process (Gupta etal. 2021). Integration of multi-omics information from many omics elds, including proteomics, metabolomics, transcriptomics, and genomes, allows for a more thorough knowledge of disease mechanisms. Using a multi-omics approach will help identify novel pharmacological targets and individualized treatment plans.

By allowing for the precise change of genes linked to specic diseases, CRISPRCas9 gene editing technology holds the potential to completely transform the medication discovery process. It opens up new possibilities for researching the genetic components of disease and creating tailored treatments (Zhang etal. 2021). There is also a growing body of research on the human microbiome. The development of microbiome-based therapies will result from the understanding that altering the microbiota can affect a broad spectrum of medical disorders. Thanks to developments in RNA interference and RNA editing technology, RNA-based therapeutics show great promise. These consist of RNA editing methods, RNAi-based therapies, and mRNA vaccinations (Qadir etal. 2020).

The 3D bioprinting and organoid technologies have made it possible to create intricate, physiologically accurate invitro models for drug testing. Preclinical testing can be enhanced by this technology, which can lessen the need for animal models (Rae etal. 2021). Post-marketing surveillance will be improved, and treatment decisions will be informed by the use of real-world data evidence, such as wearables, electronic health records, and patient-reported data. As immunotherapy treatments progress, they provide new avenues for the treatment of autoimmune disorders

240

https://t.me/med1917

and cancer. Examples of these medicines include immune checkpoint inhibitors and CAR-T cell therapy (Di Trani etal. 2022).

By drug repurposing, nding new uses for currently available pharmaceuticals is becoming more efcient, affordable, and quick with the use of computer methods and big data analysis. Nanotechnology is enabling tailored therapy, enhancing drug solubility, and creating new paths for drug administration. Additionally, it makes the advancement of customized medicine made possible by nanomedicine techniques easier. By taking a step into patient-centric drug discovery, the process of developing new drugs is increasingly including patients. Drug development and access are increasingly inuenced by patient advocacy groups, real-world evidence, and patient-reported results.

By using algorithms in AI-driven drug synthesis to forecast effective synthetic routes for drug molecules, drug synthesis can be accelerated and the time it takes to introduce new pharmaceuticals to the market can be decreased (Iskar etal. 2012). In response to the quickly changing environment, regulatory bodies are putting more exible strategies into place to expedite the licensing of drugs and simplify the research and development of ground-breaking treatments by regulatory adaptation methods. All of these upcoming developments in drug discovery are pointing towards a more patient-centred, focused, and effective method of creating new treatments. A new age in health care is expected to develop as a result of the convergence of technology, data, and scientic knowledge, which promises to uncover creative solutions to some of the most difcult health issues. These solutions will enhance patient outcomes.

J. Sundarasekar and G. Sahgal

11.9 Conclusion

In conclusion, the symbiotic integration of genomics and proteomics has unequivocally revolutionized the landscape of drug discovery. The wealth of information derived from genomic and proteomic analyses has unveiled intricate details of cellular functions, disease mechanisms, and potential therapeutic targets. Genomics, by decoding the blueprint of an individual’s genetic make-up, has facilitated the identication of genetic variations associated with diseases, enabling the development of targeted therapies. Concurrently, proteomics has elucidated the dynamic and complex protein networks governing cellular processes, offering insights into protein structures and functions crucial for drug design.

The collaborative efforts of genomics and proteomics have expedited the identication and validation of biomarkers, paving the way for personalized medicine. The ability to tailor treatments based on individual genetic and proteomic proles holds immense promise for enhancing therapeutic efcacy while minimizing adverse effects. However, amidst these remarkable advancements, challenges such as data integration, standardization, and ethical considerations persist. The evolving eld of multi-omics approaches demands continued interdisciplinary collaboration and technological innovation to harness its full potential. As we navigate the

11 Role ofGenomics andProteomics inDrug Discovery

https://t.me/med1917

241

intricate web of genomics and proteomics in drug discovery, it is evident that this holistic approach marks a paradigm shift, offering unparalleled opportunities to uncover novel drug targets and revolutionize the development of innovative and more effective therapeutic interventions. The future of drug discovery is undoubtedly intertwined with the continued exploration and renement of genomics and proteomics, propelling the pharmaceutical industry into an era of precision medicine and personalized treatment strategies.

References

Abdulmawjood B, Costa B, Roma-Rodrigues C, Baptista PV, Fernandes AR (2021) Genetic bio-

markers in chronic myeloid leukemia: what have we learned so far? Int J Mol Sci 22(22):12516 Alchakee A, Ahmed M, Eldohaji L, Alhaj H, Saber-Ayad M (2022) Pharmacogenomics in psychia-

try practice: the value and the challenges. Int J Mol Sci 23(21):13485 Alföldi J, Lindblad-Toh K (2013) Comparative genomics as a tool to understand evolution and

disease. Genome Res 23(7):1063–1068 Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q (2020) Opportunities and chal-

lenges in long-read sequencing data analysis. Genome Biol 21(1):1–6 Baloch AR, Feugang JM, Rodríguez-Osorio N (2023) Genomic and epigenomic applications in

animal and veterinary sciences. Front Vet Sci 10:1167079 Berriman M, Lustigman S, McCarter JP (2007) Genomics and emerging drug discovery technolo-

gies. Expert Opin Drug Discov 2(sup1):S83–S89 Blay V, Tolani B, Ho SP, Arkin MR (2020) High-throughput screening: today’s biochemical and

cell-based approaches. Drug Discov Today 25(10):1807–1821 Bleicher KH, Böhm HJ, Müller K, Alanine AI (2003) Hit and lead generation: beyond high-

throughput screening. Nat Rev Drug Discov 2(5):369–378 Bogatcheva E, Hanrahan C, Nikonenko B, De Los Santos G, Reddy V, Chen P, Barbosa F, Einck

L, Nacy C, Protopopova M (2011) Identication of SQ609 as a lead compound from a library

of dipiperidines. Bioorg Med Chem Lett 21(18):5353–5357 Burnier M, Wuerzner G (2015) Drug adherence monitoring in clinical trials: a necessity for a

correct assessment of the efcacy and safety of antihypertensive therapies. J Hypertens

33(12):2395–2398 Chahrour O, Cobice D, Malone J (2015) Stable isotope labelling methods in mass spectrometry-

based quantitative proteomics. J Pharm Biomed Anal 113:2 Chen S, Jiang H, Cao Y, Wang Y, Hu Z, Zhu Z, Chai Y (2016) Drug target identication using net-

work analysis: taking active components in Sini decoction as an example. Sci Rep 6(1):24245 Chiu CY, Miller SA (2019) Clinical metagenomics. Nat Rev Genet 20(6):341–355 Chow SC, Shao J, Wang H, Lokhnygina Y (2017) Sample size calculations in clinical research.

CRC, Boca Raton, FL Choy CT, Wong CH, Chan SL (2019) Embedding of genes using cancer gene expression data:

biological relevance and potential application on biomarker discovery. Front Genet 9:682 Chung CH, Levy S, Chaurand P, Carbone DP (2007) Genomics and proteomics: emerging tech-

nologies in clinical cancer research. Crit Rev Oncol Hematol 61(1):1–25 Clark KM, Jenkins JL, Fedoriw N, Dumont ME (2017) Human CaaX protease ZMPSTE

24 expressed in yeast: structure and inhibition by HIV protease inhibitors. Protein Sci

26(2):242–257 Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer

J, Bracht JW, Ito M, Karachaliou N, Rosell R (2019) Cancer stem cell biomarkers in egfr-

mutation–positive non–small-cell lung cancer. Clin Lung Cancer 20(3):167–177

242

https://t.me/med1917

Cominetti O, Núñez Galindo A, Corthésy J, Oller Moreno S, Irincheeva I, Valsesia A, Astrup A,

Saris WH, Hager J, Kussmann M, Dayon L (2016) Proteomic biomarker discovery in 1000

human plasma samples with mass spectrometry. J Proteome Res 15(2):389–399 Corsi GI, Gadekar VP, Gorodkin J, Seemann SE (2022) CRISPRroots: on-and off-target assess-

ment of RNA-seq data in CRISPR–Cas9 edited cells. Nucleic Acids Res 50(4):e20 Daly AK (2013) Pharmacogenomics of adverse drug reactions. Genome Med 5:1–2 Datta A, Kim H, McGee L, Johnson AE, Talwar S, Marugan J, Southall N, Hu X, Lal M, Mondal

D, Ferrer M (2018) High-throughput screening identied selective inhibitors of exosome bio-

genesis and secretion: a drug repurposing strategy for advanced cancer. Sci Rep 8(1):8161 Dean-Colomb W, Esteva FJ (2008) Her2-positive breast cancer: herceptin and beyond. Eur J

Cancer 44(18):2806–2812 Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo

P (2022) Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin

Drug Discov 17(1):41–53 Doak BC, Norton RS, Scanlon MJ (2016) The ways and means of fragment-based drug design.

Pharmacol Ther 167:28–37 Du Y, Li X, Niu Q, Mo X, Qui M, Ma T, Kuo CJ, Fu H (2020) Development of a miniaturized 3D

organoid culture platform for ultra-high-throughput screening. J Mol Cell Biol 12(8):630–643 Duarte Y, Márquez-Miranda V, Miossec MJ, González-Nilo F (2019) Integration of target discov-

ery, drug discovery and drug delivery: a review on computational strategies. Wiley Interdiscip

Rev Nanomed Nanobiotechnol 11(4):e1554 Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M,

Halfdanarson TR, Molina JR, Hubbard JM, Go RS (2019) Characterization of comorbidities

limiting the recruitment of patients in early phase clinical trials. Oncologist 24(1):96–102 Eddershaw PJ, Beresford AP, Bayliss MK (2000) ADME/PK as part of a rational approach to drug

discovery. Drug Discov Today 5(9):409–414 Edlin CD, Morgans G, Winks S, Duffy S, Avery VM, Wittlin S, Waterson D, Burrows J, Bryans J

(2012) Identication and in-vitro ADME assessment of a series of novel anti-malarial agents

suitable for hit-to-lead chemistry. ACS Med Chem Lett 3(7):570–573 Enck P, Klosterhalfen S (2019) Placebos and the placebo effect in drug trials. Handb Exp

Pharmacol 260:399–431 Filiou MD, Turck CW, Martins-de-Souza D (2011) Quantitative proteomics for investigating psy-

chiatric disorders. Proteomics Clin Appl 5(1–2):38–49 Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M (2006) High-throughput

screening: update on practices and success. J Biomol Screen 11(7):864–869 Gevaert K, Vandekerckhove J (2000) Protein identication methods in proteomics. Electrophoresis

21(6):1145–1154 Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P (2021) Articial intelligence to

deep learning: machine intelligence approach for drug discovery. Mol Divers 25:1315–1360 Harris RK, Wasylishen RE, Duer MJ (eds) (2009) NMR crystallography. Wiley, NewYork He YD (2006) Genomic approach to biomarker identication and its recent applications. Cancer

Biomark 2(3–4):103–133 Huang Z (2007) Drug discovery research: new frontiers in the post-genomic era. John Wiley &

Sons, NewYork Huizar CC, Raphael I, Forsthuber TG (2020) Genomic, proteomic, and systems biology approaches

in biomarker discovery for multiple sclerosis. Cell Immunol 358:104219 Ion A, Popa IM, Papagheorghe LM, Lisievici C, Lupu M, Voiculescu V, Caruntu C, Boda D (2016)

Proteomic approaches to biomarker discovery in cutaneous T-cell lymphoma. Dis Markers

2016:9602472 Iskar M, Zeller G, Zhao XM, van Noort V, Bork P (2012) Drug discovery in the age of sys-

tems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol

23(4):609–616

J. Sundarasekar and G. Sahgal

11 Role ofGenomics andProteomics inDrug Discovery

https://t.me/med1917

Issaq HJ, Veenstra TD (2008) Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE):

advances and perspectives. BioTechniques 44(5):697–700 Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase 1 clinical trial design

focused on safety, efciency, and selected patient populations: a report from the clinical trial

design task force of the national cancer institute investigational drug steering committee. Clin

Cancer Res 16(6):1726–1736 Jeffery DA, Bogyo M (2003) Chemical proteomics and its application to drug discovery. Curr

Opin Biotechnol 14(1):87–95 Jiang Z, Zhou Y (2005) Using bioinformatics for drug target identication from the genome. Am

J Pharmacogenomics 5:387–396 Jin S, Pazdur R, Sridhara R (2017) Re-evaluating eligibility criteria for oncology clinical trials:

analysis of investigational new drug applications in 2015. J Clin Oncol 35(33):3745 Johnson DE, Shaw DJ (2023) The dangerous use of genetic information. J Inf Commun Ethics

Soc 21:533 Kaiafa G, Veneti S, Polychronopoulos G, Pilalas D, Daios S, Kanellos I, Didangelos T, Pagoni S,

Savopoulos C (2021) Is HbA1c an ideal biomarker of well-controlled diabetes? Postgrad Med

J 97(1148):380–383 Kharchenko PV (2021) The triumphs and limitations of computational methods for scRNA-seq.

Nat Methods 18(7):723–732 Kim WO (2012) Institutional review board (IRB) and ethical issues in clinical research. Korean J

Anesthesiol 62(1):3–12 Kirsten N, Bulai Livideanu C, Richard MA, Konstantinou MP, Khemis A, Balluteaud C, Goujon

C, Beylot-Barry M, Paul C, French Psoriasis Research Group (2016) Inclusion and exclusion

criteria in phase III trials with systemic agents in psoriasis: the external validity of drug devel-

opment. Br J Dermatol 175(3):636–638 Knudsen DR, Raman P, Ettefa F, De Ravin L, Jose AM (2023) Target-specic requirements for

RNA interference can be explained by a single regulatory network. bioRxiv 2023:527351 Koscielny G, An P, Carvalho-Silva D, Cham JA, Fumis L, Gasparyan R, Hasan S, Karamanis N,

Maguire M, Papa E, Pierleoni A (2017) Open targets: a platform for therapeutic target identi-

cation and validation. Nucleic Acids Res 45(D1):D985–D994 Kramer R, Cohen D (2004) Functional genomics to new drug targets. Nat Rev Drug Discov

3(11):965–972 Kraus VB (2018) Biomarkers as drug development tools: discovery, validation, qualication and

use. Nat Rev Rheumatol 14(6):354–362 Kumar D, Bansal G, Narang A, Basak T, Abbas T, Dash D (2016) Integrating transcriptome and

proteome proling: strategies and applications. Proteomics 16(19):2533–2544 Lacombe O, Videau O, Chevillon D, Guyot AC, Contreras C, Blondel S, Nicolas L, Ghettas A,

Bénech H, Thevenot E, Pruvost A (2011) In vitro primary human and animal cell-based blood−

brain barrier models as a screening tool in drug discovery. Mol Pharm 8(3):651–663 Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O’Brien PJ, Fourcroy JL, Dixit R,

Pandite L, Pietrusko RG, Soares HD (2005) Method validation and measurement of biomark-

ers in nonclinical and clinical samples in drug development: a conference report. Pharm Res

22:499–511 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji

J, Sissung TM, Figg WD (2014) Phase I/Ib study of olaparib and carboplatin in BRCA1 or

BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer

Inst 106(6):dju089 Lema VM, Mbondo M, Kamau EN (2009) Informed consent for clinical trials: a review. East Afr

Med J 86(3):133–142 Lemmens T, Gibson S (2014) Decreasing the data decit: improving post-market surveillance in

pharmaceutical regulation. McGill Law J 59(4):943–988

243

244

https://t.me/med1917

Lhoumaud P, Sethia G, Izzo F, Sakellaropoulos T, Snetkova V, Vidal S, Badri S, Cornwell M,

Di Giammartino DC, Kim KT, Apostolou E (2019) EpiMethylTag: simultaneous detection of

ATAC-seq or ChIP-seq signals with DNA methylation. Genome Biol 20(1):1–2 Li XH, Li C, Xiao ZQ (2011) Proteomics for identifying mechanisms and biomarkers of drug

resistance in cancer. J Proteome 74(12):2642–2649 Li Z, Adams RM, Chourey K, Hurst GB, Hettich RL, Pan C (2012) Systematic comparison of

label-free, metabolic labeling, and isobaric chemical labeling for quantitative proteomics on

LTQ Orbitrap Velos. J Proteome Res 11(3):1582–1590 Lin Y, Mehta S, Küçük-McGinty H, Turner JP, Vidovic D, Forlin M, Koleti A, Nguyen DT, Jensen

LJ, Guha R, Mathias SL (2017) Drug target ontology to classify and integrate drug discovery

data. J Biomed Semantics 8:1–6 Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin D, Lu L, Law M (2012) Comparison of next-generation

sequencing systems. J Biomed Biotechnol 2012:1 Mäbert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A (2014) Cancer biomarker

discovery: current status and future perspectives. Int J Radiat Biol 90(8):659–677 Manjasetty BA, Büssow K, Panjikar S, Turnbull AP (2012) Current methods in structural pro-

teomics and its applications in biological sciences. 3Biotech 2:89–113 Mathai N, Chen Y, Kirchmair J (2020) Validation strategies for target prediction methods. Brief

Bioinform 21(3):791–802 Matthews H, Hanison J, Nirmalan N (2016) “Omics”-informed drug and biomarker discovery:

opportunities, challenges and future perspectives. Proteomes 4(3):28 Mayr LM, Bojanic D (2009) Novel trends in high-throughput screening. Curr Opin Pharmacol

9(5):580–588 McEwen AB, Henson CM, Wood SG (2014) Quantitative whole-body autoradiography, LC–MS/

MS and MALDI for drug-distribution studies in biological samples: the ultimate matrix trilogy.

Bioanalysis 6(3):377–391 Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whifn N, Rhodes D, Alföldi J, Trembath

RC, van Heel DA, Daly MJ (2020) Evaluating drug targets through human loss-of-function

genetic variation. Nature 581(7809):459–464 Moore N, Berdaï D, Blin P, Droz C (2019) Pharmacovigilance–the next chapter. Therapies

74(6):557–567 Ni YH, Ding L, Hu QG, Hua ZC (2015) Potential biomarkers for oral squamous cell carcinoma:

proteomics discovery and clinical validation. Proteomics Clin Appl 9(1–2):86–97 Noah JW (2010) New developments and emerging trends in high-throughput screening methods

for lead compound identication. Int J High Throughput Screen 1:141–149 Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R,

Caron H, Carleer J, Chesler L, Geoerger B (2016) Implementation of mechanism of action

biology-driven early drug development for children with cancer. Eur J Cancer 62:124–131 Qadir MI, Bukhat S, Rasul S, Manzoor H, Manzoor M (2020) RNA therapeutics: identication of

novel targets leading to drug discovery. J Cell Biochem 121(2):898–929 Rae C, Amato F, Braconi C (2021) Patient-derived organoids as a model for cancer drug discovery.

Int J Mol Sci 22(7):3483 Raj GM (2019) Pharmacogenetics, pharmacogenomics, and personalized medicine. In: Introduction

to basics of pharmacology and toxicology: Volume 1: general and molecular pharmacology:

principles of drug action. Springer, Cham, pp235–259 Raj GM, Priyadarshini R, Mathaiyan J (2015) Drug patents and intellectual property rights. Eur J

Clin Pharmacol 71:403–409 Rao VS, Srinivas K (2011) Modern drug discovery process: an in silico approach. J Bioinform Seq

Anal 2(5):89–94 Rauniyar N, Yates JR III (2014) Isobaric labeling-based relative quantication in shotgun pro-

teomics. J Proteome Res 13(12):5293–5309 Roy A (2018) Early probe and drug discovery in academia: a minireview. High Throughput 7(1):4 Saini S (2016) PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol 39:97–106

J. Sundarasekar and G. Sahgal

11 Role ofGenomics andProteomics inDrug Discovery

https://t.me/med1917

Sali A, Glaeser R, Earnest T, Baumeister W (2003) From words to literature in structural pro-

teomics. Nature 422(6928):216–225 Samuel JN, Booth CM, Eisenhauer E, Brundage M, Berry SR, Gyawali B (2022) Association of

quality-of-life outcomes in cancer drug trials with survival outcomes and drug class. JAMA

Oncol 8(6):879–886 Shah UJ, Nasiruddin M, Dar SA, Khan MK, Akhter MR, Singh N, Rabaan AA, Haque S (2020)

Emerging biomarkers and clinical signicance of HPV genotyping in prevention and manage-

ment of cervical cancer. Microb Pathog 143:104131 Shi T, Song E, Nie S, Rodland KD, Liu T, Qian WJ, Smith RD (2016) Advances in targeted pro-

teomics and applications to biomedical research. Proteomics 16(15–16):2160–2182 Siegel EB, Lakings DB (2008) Regulatory considerations. Preclinical development handbook:

toxicology. Wiley, NewYork, pp945–963 Sleno L, Emili A (2008) Proteomic methods for drug target discovery. Curr Opin Chem Biol

12(1):46–54 Stoevesandt O, Taussig MJ, He M (2009) Protein microarrays: high-throughput tools for pro-

teomics. Expert Rev Proteomics 6(2):145–157 Streiner DL, Norman GR (2009) Drug trial phases. Commun Oncol 6(1):36–40 Struk S, Jacobs A, Sánchez Martín-Fontecha E, Gevaert K, Cubas P, Goormachtig S (2019)

Exploring the protein–protein interaction landscape in plants. Plant Cell Environ 42(2):387–409 Sydor JR, Nock S (2003) Protein expression proling arrays: tools for the multiplexed high-

throughput analysis of proteins. Proteome Sci 1(1):1–7 Theilgaard-Moench K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann

A, Morgan M, Porse B, Tagliaco E, Zwaan CM, Wainscoat J (2011) Gene expression proling

in MDS and AML: potential and future avenues. Leukemia 25(6):909–920 Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, Maroyi A, Dzobo K (2018) Natural

products for drug discovery in the 21st century: innovations for novel drug discovery. Int J Mol

Sci 19(6):1578 Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ (2012) A guide to pick-

ing the most selective kinase inhibitor tool compounds for pharmacological validation of drug

targets. Br J Pharmacol 166(3):858–876 Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical consider-

ations. Circulation 113(19):2335–2362 Vemula D, Singothu S, Bhandari V (2023) Concepts in pharmacogenomics: tools and applica-

tions. In: Recent advances in pharmaceutical innovation and research, vol 12. Springer Nature

Singapore, Singapore, pp41–76 Waduge P, Tian H, Webster KA, Li W (2022) Proling disease-selective drug targets: from pro-

teomics to ligandomics. Drug Discov Today 28:103430 Waller CL, Shah A, Nolte M (2007) Strategies to support drug discovery through integration of

systems and data. Drug Discov Today 12(15–16):634–639 Wang Y, Chiu JF, He QY (2005) Proteomics in computer-aided drug design. Curr Comput Aided

Drug Des 1(1):43–52 Wang T, Liu XH, Guan J, Ge S, Wu MB, Lin JP, Yang LR (2019) Advancement of multi-target drug

discoveries and promising applications in the eld of Alzheimer's disease. Eur J Med Chem

169:200–223 Wang Y, Yang Y, Chen S, Wang J (2021) Deep DRK: a deep learning framework for drug repurpos-

ing through kernel-based multi-omics integration. Brief Bioinform 22(5):bbab048 Weeke P, Roden DM (2014) Applied pharmacogenomics in cardiovascular medicine. Annu Rev

Med 65:81–94 Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E, Blackburn H,

Loos RJ, Wareham NJ, O'Rahilly S (2013) Genome-wide SNP and CNV analysis identies

common and low-frequency variants associated with severe early-onset obesity. Nat Genet

45(5):513–517

245

246

https://t.me/med1917

Wildey MJ, Haunso A, Tudor M, Webb M, Connick JH (2017) High-throughput screening. Annu

Rep Med Chem 50:149–195 Wilson BJ, Nicholls SG (2015) The human genome project, and recent advances in personalized

genomics. Risk Manag Healthc Policy 8:9–20 Wilson FR, Coombes ME, Brezden-Masley C, Yurchenko M, Wylie Q, Douma R, Varu A, Hutton

B, Skidmore B, Cameron C (2018) Herceptin®(trastuzumab) in HER2-positive early breast

cancer: a systematic review and cumulative network meta-analysis. Syst Rev 7(1):1–7 Wright PR, Richter AS, Papenfort K, Mann M, Vogel J, Hess WR, Backofen R, Georg J (2013)

Comparative genomics boosts target prediction for bacterial small RNAs. Proc Natl Acad Sci

110(37):E3487–E3496 Xu W, Comhair SA, Chen R, Hu B, Hou Y, Zhou Y, Mavrakis LA, Janocha AJ, Li L, Zhang D,

Willard BB (2019) Integrative proteomics and phosphoproteomics in pulmonary arterial hyper-

tension. Sci Rep 9(1):18623 Yang Y, Adelstein SJ, Kassis AI (2012) Target discovery from data mining approaches. Drug

Discov Today 17:S16–S23 Yugandhar K, Gupta S, Yu H (2019) Inferring protein-protein interaction networks from mass

spectrometry- based proteomic approaches: a mini-review. Comput Struct Biotechnol J

17:805–811 Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, Moghaddam

LK, Paschepari SR, Azizi H, Torkamandi S, Tavakkoly-Bazzaz J (2017) New methods in the

diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther

24(6):233–243 Zhang HW, Lv C, Zhang LJ, Guo X, Shen YW, Nagle DG, Zhou YD, Liu SH, Zhang WD, Luan

X (2021) Application of omics-and multi-omics-based techniques for natural product target

discovery. Biomed Pharmacother 141:111833 Zheng S, Dharssi S, Wu M, Li J, Lu Z (2019) Text mining for drug discovery. Bioinformatics and

drug. Discovery:231–252 Zhou T, Yao J, Liu Z (2017) Gene ontology, enrichment analysis, and pathway analysis. In:

Bioinformatics in aquaculture: principles and methods. Wiley, NewYork, pp150–168

J. Sundarasekar and G. Sahgal

Chapter 12

https://t.me/med1917

Immunoinformatics fortheDiagnosis andMonitoring ofAutoimmune Diseases

ShaleshGangwar, NehaSharma, andDevinderToor

Abstract A complicated and diverse set of illnesses known as autoimmune dis-

eases occur when the immune system attacks healthy cells and tissues, causing tissue damage and chronic inammation. The diversity of clinical manifestations and a dearth of specic biomarkers for autoimmune disease impose difculty in the diagnosis and surveillance of it. A fresh approach known as “immunoinformatics” has been developed to assist with these difculties. The current scenario of diagnosis and monitoring of autoimmune diseases poses several disadvantages such as difculty in accurate diagnosis and often relies on expensive and time-consuming laboratory techniques which makes the idea of personalized treatments a distant reality. On the other hand, immunoinformatics serves as a potential and improved alternative to traditional approaches as it leverages computational techniques to analyse large-scale biological data, helping identify disease-specic biomarkers and prediction of immune system responses. This enables more precise diagnosis as well as assists in the planning of more personalized treatment strategies for each particular case. Immunoinformatics also aids in monitoring disease progression through continuous data analysis, allowing for adjustments to treatment plans. In this chapter, we have explored the ways in which cutting-edge digital technologies might be utilized to identify disease-specic markers for the treatment and diagnosis of autoimmune diseases.

Keywords Autoimmune diseases · Immunoinformatics · Molecular mimicry · Epitope prediction · Vaccine design · Multiple sclerosis

S. Gangwar Department of Computer Science, Jamia Millia Islamia, New Delhi, India

N. Sharma · D. Toor (*) Amity Institute of Virology and Immunology, Amity University Uttar Pradesh, Noida, India e-mail: dtoor@amity.edu

Ltd. 2024 S. Bose et al. (eds.), Concepts in Pharmaceutical Biotechnology and Drug Development, Interdisciplinary Biotechnological Advances,

https://doi.org/10.1007/978-981-97-1148-2_12

248

https://t.me/med1917

S. Gangwar et al.

12.1 Introduction

Autoimmune illnesses are a major cause of concern for the global population, affecting 14% of the whole population of the United States (NIEHS n.d.), 10% of the population of the United Kingdom (Conrad etal. 2023), and 5% of the total population of New Zealand and Australia (ASCIA 2023). The lack of identiable biomarkers and clinical heterogeneity provides considerable obstacles in effectively identifying and monitoring autoimmune diseases (Chatanaka etal. 2022).

The existing diagnostic landscape for autoimmune illnesses comes with difculties, such as the reliance on expensive and time-consuming laboratory procedures. This condition makes personalized treatments difcult to implement, contributing to a gap in addressing the particular nature of many diseases. However, “immunoinformatics”, a novel technique meant to address these diagnostic complications, represents a prospective paradigm change.

Immunoinformatics, which uses computer tools to examine large amounts of biological data, has the potential to be a game changer. This method aids in the identication of disease-specic biomarkers and the prediction of immune system responses, allowing for more exact diagnoses and the development of personalized treatment plans customized to each patient’s unique characteristics. Notably, immunoinformatics’ continuous data analysis capabilities facilitate ongoing disease progression monitoring, allowing for dynamic modications to treatment programs based on current information (Brusic and Petrovsky 2005).

In this chapter, we explore the fundamental aspects of autoimmune diseases, provide insights into the core principles of immunoinformatics, investigate its application in diagnosis, discuss its role in disease monitoring, highlight case studies and applications, and nally address the future directions and challenges within this transformative eld.

12.2 Understanding Autoimmune Diseases

A complicated and diverse set of illnesses known as autoimmune diseases arise when our immune system targets healthy cells and tissues, causing tissue damage and chronic inammation. These sets of diseases can affect various organs and organ systems, leading to varying complications. The underlying causes of many autoimmune diseases are still unknown, but an association of genetic, environmental, and immunological variables is thought to have a signicant role in their progression and development, making their association a key for the effective management and treatment of these diseases.

The aetiology of autoimmune diseases also involves an interaction between genetic predisposition and epigenetic factors. A substantial risk factor is genetic predisposition, as demonstrated by the familial clustering of some autoimmune

<<< < Предыдущая 14 15 16 17 18 19 20 21 22 23 24 2526 / 4826 27 28 29 30 31 32 33 34 35 36 37 38 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
15.09.202616 Мб0Книга_5631_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202616 Мб0Книга_5632_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5636_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5637_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5638_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5639_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5640_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5641_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5642_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202614 Мб0Книга_5643_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202614 Мб0Книга_5644_Библиотеки_им_академика_М_И_Перельмана.pdf